Kite, Juno, and BlueBird will give updates on T-cell therapies.
Investors spooked after cerebral oedema death.
Kite completes filing a day after rival Novartis.
Companies hope to challenge traiblazers Novartis and Kite.
But rival Juno finally gives up on lead therapy.
Novartis’ head of drug development talks about its stake in CAR-T immunotherapy. These cell therapies are set to transform treatment of blood cancers – but questions about safety, manufacturing and cost versus clinical value remain
Evaluate predicts sales could approach $8bn if approved.
Drug tops list compiled by Evaluate Pharma